Figure 2.

In situ vaccination with CXCL9/10-DC inhibits murine lung cancer

(A) A schematic of in vivo mouse efficacy studies. On D6 post-s.c. tumor inoculation, mice bearing ∼50-mm³ tumors were randomized and subjected to treatments as detailed in STAR Methods via IT injections on D6, D8, and D11. Tumor volumes were recorded every 2–3 days and tumor weights were measured on the day of euthanasia.

(B) FVB mice were inoculated with Kras^G12DTp53^−/−Lkb1^−/− (KPL)-3M tumor cells (1.25 × 10⁵ cells) and treated with PBS control; CXCL9 and CXCL10 recombinant proteins (CXCL9/10) at 20 ng each per injection; vector-transduced DC (Mock-DC, 2 × 10⁶ per injection); or CXCL9/10-DC (1 × 10⁶ CXCL9-DC and CXCL10-DC each per injection) (n = 6–8 mice per group).

(C) FVB mice were inoculated with KPL-3M tumor cells and treated with PBS control; CXCL9-DC (2 × 10⁶/injection); CXCL10-DC (2 × 10⁶/injection); or CXCL9/10-DC as in (B).

(D) FVB mice were inoculated with Kras^G12DTp53^−/− (KP)-3M tumor cells (2 × 10⁶ cells) and treated with PBS control or CXCL9/10-DC as in (B).

(E)129-E mice were inoculated with LKR13 (Kras^G12D) tumor cells (2 × 10⁶ cells) and treated as in (D).

(F) BALB/c mice were inoculated with L1C2 tumor cells (1 × 10⁶ cells) and treated as in (D) (n = 5–6 mice per group).

Error bars represent SEM. p values were determined by one-way ANOVA adjusting for multiple comparisons for (B) and (C), and two-tailed t test for (D–F).

∗p < 0.05; ∗∗p < 0.005; ∗∗∗p < 0.0005.